Characteristics of severe asthma patients on biologics: a real-life European registry study.
ERJ open research（2023）
摘要
A large proportion of patients in the SHARP registry would not have been eligible for anti-IL5(R) treatment in RCTs, demonstrating the importance of real-life cohorts in describing the efficacy of biologics in a broader population of patients with severe asthma.
更多查看译文
关键词
severe asthma patients,biologics,european registry study,real-life
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要